research compound raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-05. Anything still debated is marked as such rather than presented as settled.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
== Traditional use == Peach gum has been documented in traditional Chinese medicine texts, including the Tang Bencao (Tang Materia Medica) and Li Shizhen's Bencao Gangmu (Compendium of Materia Medica) from the Ming Dynasty. Historical texts describe its use for treating urinary issues and other conditions, though these traditional uses have not been validated by modern scientific research.
== Part 1 == This 90-minute video shows how Metallica and their producer Bob Rock worked their way through making the Metallica album. It also includes the making of the video for "Enter Sandman" and also a listening party for invited fans to come and listen to the album in full. The video as well highlights tensions between Bob Rock and Metallica. The infamous exchange between Kirk Hammett and Bob Rock during the recording of "The Unforgiven" guitar solo is documented. This video also includes three of the music videos the band shot for that album:
Trump declared that the United States "[does] not need the help of anyone" regarding the war. In the morning of 17 March, senior Iranian officials, including Ali Larijani and Basij chief Gholamreza Soleimani were targeted by Israeli airstrikes. Both their deaths were later confirmed by Iranian state media. In response, Iran launched a missile barrage that killed two Israeli civilians in Ramat Gan. The same day, Israel launched a ground invasion of southern Lebanon.
(2026) determine the distribution of habitats suitable for Neanderthals and modern humans in Europe during stadial and interstadial events of Marine Isotope Stage 3, providing evidence of a shift but not complete disappearance of habitats suitable for Neanderthals as a result of climate changes, weak connectivity between optimal regions for Neanderthals, and overlaps between optimal regions of the two hominins. A Neanderthal infant assigned to the 6- to 14-month age range, providing evidence of rapid somatic growth in early life of Neanderthals, is described from the Amud Cave (Israel) by Been et al. (2026). Blinkhorn et al. (2026) study the variability of Levallois blanks from northeast Africa and southwest Asia, and interpret Levallois stone tools from northern Arabia dating to early Marine Isotope Stage 3 as likely produced by Neanderthals. Evidence from the study of palynological assemblages from the Axlor site (Spain), indicative of marked shifts in landscape structure at the time of the Neanderthal occupation of the site, is presented by Pérez-Díaz et al. (2026). Evidence of short-term Neanderthal occupations of the Eirós cave (Spain), indicative of high mobility of late Neanderthal communities from northwestern Iberian Peninsula, is presented by Rodríguez-Álvarez et al. (2026). Fotiadou et al.
== Epidemiology == In European populations, cellulite is thought to occur in 80–90% of post-adolescent females. Its existence as a real disorder has been challenged, and the prevailing medical opinion is that it is merely the "normal condition of many women". It is rarely seen in males.
Sources: en.wikipedia.org
Becker muscular dystrophy (BMD) is an X-linked recessive inherited disorder characterized by slowly progressing muscle weakness of the legs and pelvis. It is a type of dystrophinopathy. The cause is mutations and deletions in any of the 79 exons encoding the large dystrophin protein, essential for maintaining the muscle fiber's cell membrane integrity. Becker muscular dystrophy is related to Duchenne muscular dystrophy in that both result from a mutation in the dystrophin gene, however, the hallmark of Becker is milder in-frame deletions. and hence has a milder course, with patients maintaining ambulation till 50–60 years if detected early. While there is no known cure, management strategies such as physical therapy, braces, and corrective surgery may alleviate symptoms. Assisted ventilation may be required in those with weakness of breathing muscles. Several drugs designed to address the root cause are currently available including gene therapy (Elevidys). Other medications used include glucocorticoids (Deflazacort, Vamorolone); calcium channel blockers (Diltiazem); to slow skeletal and cardiac muscle degeneration, anticonvulsants to control seizures and some muscle activity, and Histone deacetylase inhibitors (Givinostat) to delay damage to dying muscle cells. These patients do not require antisense drugs (Ataluren, Eteplirsen, etc.) as a certain percentage of dystrophin is already expressed.
The two substrates of this enzyme are ethyl (R)-3-hydroxyhexanoate and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are ethyl 3-oxohexanoate, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is ethyl-(R)-3-hydroxyhexanoate:NADP+ 3-oxidoreductase. This enzyme is also called 3-oxo ester (R)-reductase.
Genetic studies of Xanthoria parietina have revealed significant differentiation among populations, with genetic variation structured by both geographic distance and substrate type. Populations growing on tree bark show higher genetic diversity than those on rock surfaces, though there is no evidence of restricted gene flow between populations on the same substrate type, even when separated by distances of up to 25 km (16 mi). Despite these genetic differences, no corresponding morphological or chemical variation has been observed. At fine spatial scales, X. parietina exhibits high genetic diversity within local populations, with most genetic variation (up to 90%) occurring within rather than between populations. Studies using IGS and ITS (genetic markers used to assess variation) reveal significant diversity even among closely located individuals. Research from Storfosna island, Norway, suggests long-term local adaptation to bark or rock habitats has led to habitat-specific genetic variants, shaping the overall population structure. While local populations may have limited genetic diversity, populations from different geographic regions show significant genetic differentiation. For example, Antarctic populations of Rusavskia elegans from sites just 5–15 km (3.1–9.3 mi) apart differed by one nucleotide. In contrast, those separated by 660 km (410 mi) showed a 14.2% divergence in their DNA sequences.
The Boston keratoprosthesis is the most widely used synthetic cornea to date with over 900 procedures performed worldwide in 2008. The Boston KPro was developed at the Massachusetts Eye and Ear Infirmary under the leadership of Claes Dohlman.
With ring-opening polymerization, automated synthesis has been used for rapid screening and optimization, including with catalyst + initiator systems and their polymerization conditions. For example, Hoogenboom et al. determined the optimal temperature for the polymerization of 2-ethyl-2-oxazoline in dimethylacetamide (DMAc), allowing for individual heating of the parallel reactors, which shortened the time needed for preparation and analysis. To aid with the catalyst research for polyolefins, Symyx Technologies Inc. used automated synthesis to create a library of palladium and nickel catalysts, which were screened for ethylene polymerization. This process found that the largest polyethylene polymers were created by the complexes with the highest steric hindrance for the ortho-positions of the aryl rings, while electronic factors did not influence yield or molecular weight. In addition, Tuchbreiter and Mülhaupt used automated synthesis to demonstrate the improvements of minireactors for the polymerization of olefins, with quality improving as compared to utilizing simple arrays.
Sources: en.wikipedia.org
Waters was involved in mentorship of chemistry students from nontraditional and disadvantaged backgrounds as part of the American Chemical Society's Project SEED. She has advanced multiple campus groups encouraging women scholars in physical sciences. Waters mentored for TANDEMplusIDEA, the international mentoring program for female scientists from 2007 to 2009. Waters was on the board of directors for the Mesilla Chemistry Workshop held in July from 2006 to 2018. From 2011 to 2013, Waters was a UNC WOWS Scholar (Working on Women in Science). From 2013 to 2018, she was a Faculty Advisor for UNC WISE (Women in Science and Engineering, graduate student organization).
Sulfide oxidation is performed by both bacteria and archaea in a variety of environmental conditions. Aerobic sulfide oxidation is usually performed by autotrophs that use sulfide or elemental sulfur to fix carbon dioxide. The oxidation pathway includes the formation of various intermediate sulfur species, including elemental sulfur and thiosulfate. Under low oxygen concentrations, microbes will oxidize to elemental sulfur. This elemental sulfur accumulates as sulfur globules, intracellularly or extracellularly, to be consumed under low sulfur concentrations. To ameliorate low oxidant concentrations (that is, to find an electron sink), sulfur oxidizers like cable bacteria form long chains that span the length between oxic and sulfidic zones of the coastal sediments. The bacteria present in the sulfide rich zones oxidize the sulfide and transport the electrons to the bacteria present in the oxygen rich zone through multiple periplasmic strings where the oxygen is reduced.
Seizures are characterized by high levels of synchronized neuronal activity. One important regulator of neuronal activity is the hyperpolarizing A-type current mediated by potassium channel KV4.2. miR-324-5p downregulates KV4.2, exacerbating conditions that lead to seizure onset, and downregulation of miR-324-5p in mouse models of epilepsy is seizure-suppressive. Changes in miRNA expression are seen in epileptogenesis and in other disease pathologies. In epilepsy, miR-324-5p expression has been shown to increase and decrease at different timepoints and loci. Importantly, miR-324-5p has increased association with the RISC complex following seizure in mice, indicating more suppressive activity. Overall, this suggests that miR-324-5p plays a role in epileptogenesis via targeting of potassium channel KV4.2. miR-324-5p contributes to cardiac disease pathophysiology and cardiomyocite death through translational inhibition of Mtfr1, leading to reduced mitochondrial fission, apoptosis, and myocardial infarction.
According to the United States Geological Survey (USGS), 10,200 tonnes of bismuth were produced worldwide by mining and 17,100 tonnes by refining in 2016. Since then, USGS does not provide mining data for bismuth, considering them unreliable. Globally, bismuth is mostly produced by refining, as a byproduct of extraction of other metals such as lead, copper, tin, molybdenum, and tungsten, though the refining-to-mining ratio depends on the country. Bismuth travels in crude lead bullion (which can contain up to 10% bismuth) through several stages of refining, until it is removed by the Kroll-Betterton process, which separates the impurities as slag, or the electrolytic Betts process. Bismuth behaves similarly with another of its major metals, copper. The raw bismuth metal from both processes contains still considerable amounts of other metals, foremost lead. By reacting the molten mixture with chlorine gas, the metals are converted to their chlorides, while bismuth remains unchanged. Impurities can also be removed by various other methods, for example, with fluxes and treatments yielding high-purity bismuth metal (over 99% Bi).
=== Hepatotoxicity === Moderate to severe acute hepatitis has occurred in several adults who had been taking the drug at the recommended dose for two to four weeks. Plasma rosiglitazone concentrations may be increased in people with existing liver problems.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.